JP5847827B2 - Ｔｒｐａ１受容体アンタゴニスト - Google Patents

Ｔｒｐａ１受容体アンタゴニスト Download PDF

Info

Publication number
JP5847827B2
JP5847827B2 JP2013533819A JP2013533819A JP5847827B2 JP 5847827 B2 JP5847827 B2 JP 5847827B2 JP 2013533819 A JP2013533819 A JP 2013533819A JP 2013533819 A JP2013533819 A JP 2013533819A JP 5847827 B2 JP5847827 B2 JP 5847827B2
Authority
JP
Japan
Prior art keywords
pain
compound
various
pharmaceutically acceptable
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013533819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013539781A5 (https=
JP2013539781A (ja
Inventor
マッツ・スヴェンソン
ディルク・ヴァイゲルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2013539781A publication Critical patent/JP2013539781A/ja
Publication of JP2013539781A5 publication Critical patent/JP2013539781A5/ja
Application granted granted Critical
Publication of JP5847827B2 publication Critical patent/JP5847827B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2013533819A 2010-10-12 2011-10-11 Ｔｒｐａ１受容体アンタゴニスト Expired - Fee Related JP5847827B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39213010P 2010-10-12 2010-10-12
US61/392,130 2010-10-12
PCT/SE2011/051213 WO2012050512A1 (en) 2010-10-12 2011-10-11 Trpa1 receptor antagonist

Publications (3)

Publication Number Publication Date
JP2013539781A JP2013539781A (ja) 2013-10-28
JP2013539781A5 JP2013539781A5 (https=) 2014-10-23
JP5847827B2 true JP5847827B2 (ja) 2016-01-27

Family

ID=45938532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533819A Expired - Fee Related JP5847827B2 (ja) 2010-10-12 2011-10-11 Ｔｒｐａ１受容体アンタゴニスト

Country Status (5)

Country Link
US (1) US8859556B2 (https=)
EP (1) EP2627329B1 (https=)
JP (1) JP5847827B2 (https=)
CN (1) CN103153308B (https=)
WO (1) WO2012050512A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087501A1 (es) 2011-08-09 2014-03-26 Hydra Biosciences Inc Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1
WO2013108857A1 (ja) 2012-01-17 2013-07-25 味の素株式会社 複素環アミド誘導体及びそれを含有する医薬
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
WO2014184248A2 (en) * 2013-05-15 2014-11-20 Acturum Life Science AB Trpa1 antagonist compounds
CN103760286A (zh) * 2014-01-14 2014-04-30 北京万全德众医药生物技术有限公司 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012287A1 (en) * 2003-08-01 2005-02-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AU2006327181A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
GB0614037D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
WO2009089082A1 (en) 2008-01-04 2009-07-16 Abbott Laboratories Trpa1 antagonists
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
TW201026700A (en) * 2008-12-22 2010-07-16 Hydra Biosciences Inc Compositions useful for treating disorders related to TRPA1

Also Published As

Publication number Publication date
CN103153308A (zh) 2013-06-12
WO2012050512A1 (en) 2012-04-19
JP2013539781A (ja) 2013-10-28
CN103153308B (zh) 2015-06-03
US8859556B2 (en) 2014-10-14
EP2627329B1 (en) 2015-07-08
EP2627329A4 (en) 2014-03-05
US20140148466A1 (en) 2014-05-29
EP2627329A1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
JP5847827B2 (ja) Ｔｒｐａ１受容体アンタゴニスト
EP2493313B1 (en) Kinase inhibitors
US11484525B2 (en) Mu opioid receptor modulators
JP7102012B2 (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
CN103917534B (zh) 作为h3受体抑制剂的包含哌啶和哌嗪环的氨基甲酸酯/脲衍生物
US11345666B2 (en) Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
CA2938212A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
JP7746259B2 (ja) 核内受容体に対して活性の化合物
TW200303199A (en) Novel pyridin-and pyrimidin-derivatives
JPWO2020017587A1 (ja) ピリダジノン誘導体
MX2015003637A (es) Piridinonas biciclicas novedosas.
KR20160054570A (ko) 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자
JP6880166B2 (ja) スルタム化合物及びその使用方法
US10501466B2 (en) WDR5 inhibitors and modulators
CN108368060A (zh) 一类新型的嘧啶类衍生物激酶抑制剂
WO2023049480A1 (en) Substituted phenylalkylamines
EP3022201A1 (en) Autotaxin inhibitors
JP2025183239A (ja) 小分子エナンチオマーによるアンドロゲン受容体調節
US9975873B2 (en) Isoindoline derivatives
CN112020354A (zh) 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途
US20130184294A1 (en) Pyrimidones for Treatment of Potassium Channel Related Diseases
KR20230170684A (ko) Lrrk2 키나제 억제제로서 유용한 피리미딘 유도체
JP2019524899A (ja) 障害の治療のためのヒドロキシノルケタミン誘導体
JP2025537554A (ja) アリールシクロアルキルアミド構造を有するイソインドリノン誘導体及びその用途
AU2024324533A1 (en) Compounds and compositions for modulating the activity of erk

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151125

R150 Certificate of patent or registration of utility model

Ref document number: 5847827

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees